Other analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Galapagos NV from a hold rating to a buy rating and set a $61.00 target price on the stock in a report on Wednesday, July 13th. Janney Montgomery Scott assumed coverage on shares of Galapagos NV in a report on Tuesday, August 30th. They set a buy rating and a $64.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of €67.80 ($74.51).
Galapagos NV (NASDAQ:GLPG) traded down 1.05% during mid-day trading on Tuesday, reaching $66.10. 23,236 shares of the company were exchanged. The stock’s market capitalization is $3.05 billion. The company’s 50 day moving average price is $62.06 and its 200-day moving average price is $54.39. Galapagos NV has a 12 month low of $37.03 and a 12 month high of $73.37.
Hedge funds have recently added to or reduced their stakes in the company. Fiera Capital Corp purchased a new stake in Galapagos NV during the second quarter worth $302,000. Citadel Advisors LLC purchased a new stake in Galapagos NV during the second quarter worth $347,000. A.R.T. Advisors LLC purchased a new stake in Galapagos NV during the first quarter worth $547,000. Landscape Capital Management L.L.C. boosted its stake in Galapagos NV by 114.7% in the first quarter. Landscape Capital Management L.L.C. now owns 17,389 shares of the company’s stock worth $727,000 after buying an additional 9,288 shares during the period. Finally, P.A.W. Capital Corp purchased a new stake in Galapagos NV during the second quarter worth $1,109,000. 21.21% of the stock is currently owned by institutional investors and hedge funds.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.